key: cord-0903457-jfdwo189
authors: Vijayakumar, Bavithra; Tonkin, James; Devaraj, Anand; Philip, Keir E. J.; Orton, Christopher M.; Desai, Sujal R.; Shah, Pallav L.
title: CT Lung Abnormalities after COVID-19 at 3 Months and 1 Year after Hospital Discharge
date: 2021-10-05
journal: Radiology
DOI: 10.1148/radiol.2021211746
sha: e63901aa63f75c98d9d80c3bf659e7de597e7241
doc_id: 903457
cord_uid: jfdwo189

BACKGROUND: Data on the long-term pulmonary sequelae in COVID-19 are lacking. PURPOSE: To assess symptoms and functional impairment and residual pulmonary abnormalities on serial chest CT in COVID-19 survivors discharged from hospital at up to 1-year follow-up. MATERIALS AND METHODS: Adult patients with COVID-19 discharged between March 2020 and June 2020 were prospectively evaluated at 3 months and 1 year, through systematic assessment of symptoms, functional impairments, and thoracic CT as part of the PHENOTYPE study, an observational cohort study in COVID-19 survivors. Lung function testing was limited to participants with CT abnormalities and/or persistent breathlessness. All statistical analyses were performed using Graphpad PRISM Version 9.0 (86) for Mac, GraphPad Software, (www.graphpad.com); Bonferroni corrected p values are stated. RESULTS: Eighty participants (mean age, 59 ±13 years; 53 men) were assessed. Persistent breathlessness 37 (46%) and cough 17 (21%) were reported at outpatient review (median 97 days [IQR 86-121]). CT scans in 73 participants post-discharge (median 105 days [IQR 95-141]) revealed persistent abnormalities in 41/73 participants (56%), with ground-glass opacification (35/73 [48%]) and bands (27/73 [37%]) predominating. Unequivocal signs indicative of established fibrosis (i.e. volume loss +/- traction bronchiectasis) were present in 9/73 (12%) participants. Higher admission serum C-reactive protein (mg/L), fibrinogen (g/dl), urea (mmol/L) and creatinine (micromol/L), longer hospital stay (days), older age (years) and requirement for invasive ventilation were associated with CT abnormalities at 3-month follow-up. 32/41 (78%) of participants with abnormal 3-month follow-up CT underwent repeat imaging at a median of 364 (360-366) days, with 26/32 (81%) showing further radiological improvement (median 18% [IQR 10–40%]). CONCLUSION: CT abnormalities were common at 3 months after COVID-19 but with signs of fibrosis in a minority. More severe acute disease was linked with CT abnormalities at 3 months. However, radiologic improvement was seen in the majority at 1-year follow-up. ClinicalTrials.gov Identifier: NCT04459351

I n p r e s s (years) and requirement for invasive ventilation were associated with CT abnormalities at 3month follow-up. 32/41 (78%) of participants with abnormal 3-month follow-up CT underwent repeat imaging at a median of 364 (360-366) days, with 26/32 (81%) showing further radiological improvement (median 18% [IQR 10-40%]).

CT abnormalities were common at 3 months after COVID-19 but with signs of fibrosis in a minority. More severe acute disease was linked with CT abnormalities at 3 months.

However, radiologic improvement was seen in the majority at 1-year follow-up.

ClinicalTrials.gov Identifier: NCT04459351

The novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, was designated a pandemic by the World Health Organization in March 2020 1 . As of Sep 1, 2021, there have been over 217 million cases and over 4.5 million deaths because of COVID- 19. 2 In addition to substantial mortality, a large proportion of COVID-19 survivors suffer persistent morbidity, with symptoms including breathlessness, fatigue, and lowered qualityof-life measures. [3] [4] [5] These symptoms mirror data from the severe acute respiratory syndrome (SARS-1) and middle eastern respiratory virus (MERS) pandemics. [6] [7] [8] Breathlessness has been reported in over half of patients post COVID-19, 3 with females under the age of 50 more likely to experience this. 9 But the underlying aetiology and natural history of pulmonary sequelae after COVID-19 are unclear. One postulate is that respiratory symptoms in survivors might be attributable to pulmonary fibrosis, as reported following other coronavirus 10, 11 and influenza 12 pandemics. In this context, fibrosis due to acute respiratory distress syndrome (ARDS) 13, 14 or indeed virus-induced initiation or propagation of interstitial lung disease 15, 16 is possible.

Radiologic and physiologic abnormalities in COVID-19 survivors have been described, with ground-glass opacification (GGO) and bands being the common findings. [17] [18] [19] [20] Post-COVID-19 diagnoses of fibrosis have also been made but largely in the absence of histopathologic findings and using a variety of non-standard radiologic descriptors such as "fibrotic strips" I n p r e s s and "irregular lines" with small patient cohorts recovering from severe disease 18, 21 and the majority with relatively short-term (up to 6 months) follow-up. [22] [23] [24] [25] Studies evaluating serial radiologic changes after COVID-19 are lacking. Therefore, the aim of the present study was to critically review chest CT abnormalities in survivors at up to 1-year follow-up in concert with symptomatology and indices of functional impairment, identify associations with inpatient characteristics, and evaluate serial radiologic findings. Participants with an abnormal CT at 3 months, were invited for a repeat at 1 year after discharge coupled with assessment of self-reported breathlessness and lung function.

CT scans performed during the participants' inpatient stay were not used for analysis in this study.

All CT scans were reviewed by two thoracic radiologist observers (AD and SRD, with over 20 years' experience respectively) blinded to all clinical and functional data. By consensus, observers quantified i) the overall extent of opacified lung and, of the abnormally opacified lung, ii) the proportional extents of the following radiological patterns: a) ground-glass opacification, b) consolidation, c) linear or curvilinear band opacities and d) reticulation, all to the nearest 5%. The presence or absence of volume loss in individual I n p r e s s lobes was recorded (0= volume loss not present; 1=volume loss present). Finally, the presence/severity of traction bronchiectasis / bronchiolectasis (0=none; 1=mild; 2=moderate and 3=severe) was graded semi-quantitatively and, when present, the number of lobes affected was recorded (up to a maximum score of 6 [NB the lingula was scored as a separate lobe]).

CT scans performed at 1-year were compared side-by-side with the 3-month followup scan. For the 1-year CTs, observers recorded whether there had been i) improvement, ii) deterioration or iii) stability compared with the 3-month CT scan. Persistent abnormalities on the 1-year scan were quantified in the same manner as for the 3-month scan (see above).

Continuous variables were expressed as medians and interquartile ranges (IQR) or mean +/-standard deviation (SD). Categorical variables were analyzed using numbers and percentages. Comparisons between groups were performed using the two-sample student's T test or Mann-Whitney U test, as appropriate. Paired testing using Wilcoxon signed rank test was used to compare changes in CT scores. Categorical data were compared using Chisquared testing. Missing data within Leicester cough questionnaire were accounted for by amending the scoring formula. Spearman rank correlation method was used. A p value <0.05 was considered statistically significant. All statistical analyses were performed by BV using Graphpad PRISM Version 9.0 (86) for Mac, GraphPad Software, (www.graphpad.com).

Bonferroni corrections are used as appropriate.

Eighty participants (mean age, 59±13 (SD) years; 53 men) were assessed. Table 1 shows the baseline demographics, inpatient, and follow-up characteristics. Figure 1 highlights the enrollment process. The initial follow-up visit was conducted at a median of 97 days (IQR, 86-121 days) after discharge. Over half (51%) of participants were from black, Asian and minority ethnic (BAME) backgrounds. Common co-morbidities included hypertension (29%), type II diabetes mellitus (23%) and asthma (14%). The majority of participants had no previous respiratory (81%) or cardiovascular co-morbidity (70%) and 53% were lifelong non-smokers. The median duration of hospital stay was 8 (IQR 3-15) days, with 40% of participants requiring level 2 or 3 ventilatory support in the form of mechanical ventilation or non-invasive positive pressure ventilation which includes continuous positive airway pressure or bi-level positive airway pressure ventilation.

Acute pulmonary embolism (PE), requiring therapeutic anticoagulation, was recorded in 8.8% (n=7) participants during the acute admission. All participants with PE had needed mechanical ventilation (n=4) or positive pressure ventilation (n=3).

Persistent cough (17/80) [21%]) and breathlessness (37/80 [46%]) were the commonest respiratory symptoms at the 3-month follow up, with a deterioration in the mMRC score in the majority of participants reporting breathlessness (29/37 [78%]) (Table   E1 ).

Blood results at admission and 3-month follow-up can be found in Tables E2 and E3 .

Whilst the majority of blood abnormalities had resolved at follow-up, a raised CRP (13/80 [16%]), raised fibrinogen (7/76 [9.2%]), abnormal ferritin (11/79 [14%] ) and raised D-dimer (14/79 [18%] were commonly seen. The median age of participants with CT features of fibrosis was 59 years (IQR 56-67).

Median length of hospital stay was 22 days (IQR 5-50); 8/9 (89%) were male and the majority, 7/9 (78%), were from a BAME background with the following co-morbidities: type II diabetes mellitus (6/9 [67%], hypertension (5/9 [55%]), ischaemic heart disease and hypercholesterolaemia (both 2/9 [22%]) and asthma (1/9 [11%]). Additionally, 3/9 (33%) I n p r e s s required positive pressure ventilation, 5/9 (55%) required mechanical ventilation whereas 1/9 (11%) warranted oxygen therapy alone. (Table 2) Based on the overall CT extent of abnormal lung, participants were divided into three severity groups, defined as follows: mild (<30% abnormal lung), moderate (30 to <60%), and extensive (≥60%). In those with persistent CT abnormalities at follow-up, 51%

(n=21) were categorized mild, 17 % (n=7) moderate and 32% (n=13) as extensive.

We found no evidence of a difference in participant-reported breathlessness between those with and without CT abnormalities ( 

The relationships between CT abnormalities and i) levels of respiratory support required and ii) admission blood parameters are shown in Table 3 and Figure 4 (and Figure   E1 ) respectively. Abnormalities on 3-month CT were related to length of hospital stay (17 +/-17 vs 7.4 +/-7.1 days, p=.008), age (62+/-10 vs 57+/-12 years, p=.04), and admission blood markers: C-reactive protein, fibrinogen, urea and creatinine. The proportion of participants with an abnormal CT at follow-up was higher in participants requiring mechanical I n p r e s s ventilation (odds ratio, OR=7.8; 95% CI=1.7-36.1; p=.004) and in those requiring mechanical ventilation or positive pressure ventilation (OR=4.1; 95% CI=1.5-10.7; p=.006). Table 4 shows the demographics, admission data and blood abnormalities in greater detail.

We found no evidence of differences in the time interval ( Figure E4 and Table E5 show the cohort undergoing repeat imaging; CT from one patient, treated with corticosteroid after discharge, was excluded. 1-year follow-up CT scans were normal in 5/32 (16%) participants and stable in 6/32 (19%) with no change in the overall extent of abnormalities (median residual overall extent, 7.5% (IQR 5-17.5%, CI 5-25%), ground-glass opacification 5% (IQR 0-10.8, CI 0-25%) and bands 2.5% (IQR 0-6%, CI 0-9%). In 21/32 (66%) there was improvement with a median reduction in extent of 17.5% (IQR 10-40%, CI 10-35%) in overall extent, 11.5% (1.9-39.8%, CI 4-35%) in ground-glass opacification and 0.5% (0-2.5%, CI 0-2%) in bands. Figure 5 and participants at a median of 365 days (IQR, 362 -376 days) after discharge (Table E6 ]. There was no correlation between the residual overall CT extent at 1 year and lung function parameters ( Figure E5 ).

We found evidence of statistically significant improvements in the overall CT extent of abnormality and the extent of ground-glass opacification but not bands at 1-year follow-I n p r e s s up when compared with the CT at 3 months. As compared with band opacities, the reduction in extent of ground-glass opacification was more striking and there was a positive correlation between improvement in overall CT scores and both the ground-glass component (r = 0.88 p <0.001) and bands (r = 0.74, p = .001). [ Figure 7 and Figure E6 ]. There was no evidence of progressive disease on sequential imaging. Lung fibrosis is known to complicate diffuse alveolar damage (DAD) or acute respiratory distress syndrome (ARDS). Indeed, a fibroproliferation phase, of variable severity, is part of the natural history of DAD. 14,33,34 Furthermore, fibrosis in patients with ARDS may be iatrogenic, caused by barotrauma 35 therefore some of the features seen on CT post COVID-19 may be a consequence of mechanical ventilation or associated lung injury, rather than due to COVID-19. Recent data suggest that the prevalence of fibrosis after COVID-19 ranges from 39% to 67%. 18, 21, 36, 37 However, the reliance almost wholly on CT features (without histopathologic corroboration) and vague terminology is problematic.

Non-specific radiologic terms (for instance, fibrotic bands or stripes) and the amalgamation of different radiologic signs -including parenchymal bands, traction bronchiectasis, and I n p r e s s honeycombing -under a generic 'fibrotic group' warrants scrutiny. Finally, inter-observer variability for interpreting non-specific signs such as 'irregular interfaces' adds a further challenge, which is seldom highlighted in earlier studies. 38 In our study, the dominant CT patterns at follow-up were ground-glass opacification and linear/curvilinear bands. Ground-glass opacification on CT indicates a region of lung from which air has been partially displaced. 39 Accordingly, ground-glass opacification may be a manifestation of an interstitial lung disease, air space pathology, or some combination of the two. 40 In COVID-19 survivors, we postulate that ground-glass opacities (in the absence of traction bronchiectasis) represent resolving DAD/ARDS, in which there is significant histopathologic heterogeneity. 41 Therefore, making a diagnosis of established lung fibrosis on the basis of ground-glass opacification alone may overestimate the prevalence of fibrosis. 34 The view that all bands denote fibrosis is also presumptuous: other pathologic processes, for instance subsegmental atelectasis 35 and organizing pneumonia 42 (incidentally, a frequent pathologic finding in COVID-related ARDS), 38 may manifest in this way on CT. One of the strengths of our study is that in contrast with earlier studies, we have restricted our CT evaluation to accepted radiologic terms. 40 We have also captured the spectrum of disease severities requiring hospital admission, rather than restricting our cohort to participants requiring level 2/ 3 ventilatory support -a sub-group more likely to have significant sequelae and over-represented in current literature. 18, 21 Our study has limitations: first, the absence of histopathologic confirmation is a limitation of our study making inferences based on surrogate CT signs mandatory. Second, our study includes a relatively small numbers of study participants. Therefore, it is also possible that I n p r e s s some relationships between variables were not identified due to underpowering, particularly in relation to subgroup analyses. 18, 21 Third, we had a limited proportion of participants with full lung function results. Fourth, breathlessness was assessed using participant-reported symptoms and the mMRC score. The latter score has a limited range of options and can be difficult to interpret. Furthermore, calculating pre-morbid mMRC is prone to recall bias. Especially in this cohort, difficulty differentiating between breathlessness and fatigue, weight gain between visits and deconditioning, question the validity and aetiology of patient-reported breathlessness, which may explain the lack of association between patient-reported breathlessness and persistent radiologic findings.

Finally, multiple hypotheses testing means that a p value of <0.05 might not necessarily be statistically significant.

In summary, this study has shown that patient symptoms, abnormalities on CT and changes in lung function are relatively common following COVID-19 infection and may persist well up to 12 months post discharge. In 81% (26/32) study participants, radiologic abnormalities regressed further between the 3 month and 12 month CT scan. Data from larger cohorts undergoing longer follow-up are likely to further clarify these results. Tables   Table E1: 

WHO Coronavirus Disease (COVID-19) Dashboard

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax; 76. Epub ahead of print

Persistent Symptoms in Patients After Acute COVID-19. JAMA; 324. Epub ahead of print

Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax; 76. Epub ahead of print

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax; 60. Epub ahead of print

Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection

SARS: prognosis, outcome and sequelae. Respirology; 8. Epub ahead of print

Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. Medrix reviews

Thin-Section Computed Tomography Manifestations During Convalescence and Long-Term Follow-Up of Patients with Severe Acute Respiratory Syndrome (SARS)

CT Correlation With Outcomes in 15 Patients With Acute Middle East Respiratory Syndrome Coronavirus

Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection

The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance

Pulmonary fibrosis in severe acute respiratory failure

Viruses as co-factors for the initiation or exacerbation of lung fibrosis

SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis

A prospective study of 12-week respiratory outcomes in COVID-19-related hospitalisations. Thorax; 76. Epub ahead of print

Pulmonary function and radiological features four months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet; 395. Epub ahead of print

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax; 76. Epub ahead of print

High Prevalence of Pulmonary Sequelae at 3 Months after Hospital Discharge in Mechanically Ventilated Survivors of COVID-19. American Journal of Respiratory and Critical Care Medicine; 203. Epub ahead of print

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet; 397. Epub ahead of print

Fibrotic Interstitial Lung Abnormalities at 1-year Follow-up CT after Severe COVID-19. Radiology. Epub ahead of print

Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology; 299. Epub ahead of print

Postacute Sequelae of COVID-19 Pneumonia: 6-month Chest CT Follow-up. Radiology. Epub ahead of print

Medical Research Council PHNSASS 1ET

Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax; 58. Epub ahead of print April 1

The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. Chest; 128. Epub ahead of print

Thin-Section CT in Patients with Severe Acute Respiratory Syndrome Following Hospital Discharge: Preliminary Experience. Radiology; 228. Epub ahead of print

Six month radiological and physiological outcomes in severe acute respiratory syndrome (SARS) survivors. Thorax; 59. Epub ahead of print October 1

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax; 60. Epub ahead of print

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. The Lancet Respiratory Medicine. Epub ahead of print

Causes of mortality in patients with the adult respiratory distress syndrome

Fibroproliferation Occurs Early in the Acute Respiratory Distress Syndrome and Impacts on Outcome. American Journal of Respiratory and Critical Care Medicine; 162. Epub ahead of print

Acute Respiratory Distress Syndrome: CT Abnormalities at Long-term Follow-up. Radiology; 210. Epub ahead of print

Imaging features and evolution on CT in 100 COVID-19 pneumonia patients in Wuhan, China. European Radiology; 30. Epub ahead of print

Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge

Interstitial Lung Disease after COVID-19 Infection: A Catalog of Uncertainties. Radiology; 299. Epub ahead of print

Fleischner Society: Glossary of Terms for Thoracic Imaging. Radiology; 246. Epub ahead of print

Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease: pathologic-CT correlation. Radiology; 189. Epub ahead of print

Primers; 5. Epub ahead of print December 14

Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge

D dimer (microgram/L) (<500)

Laboratory reference ranges are quoted next to each lab parameter

I n p r e s s performed using Mann Whitney U or two-sample student T test, or Chi squared test, with odds ratio and 95% CIs.Results are presented as number (%n), mean (+/-SD) or median (IQR) I n p r e s s Figure E1: (A-D) Scatterplots showing relationship between admission blood parameters, age and length of stay in those with CT changes at 3 months, relative to those without. Comparisons made using student's T test (two-sample) and Mann Whitney U test. Median and interquartile ranges shown. I n p r e s s